Nestle, Zydus, Abbott face India scrutiny over children’s product claims
ABT•India’s food safety regulator issued notices to Nestle India, Zydus Wellness, Abbott Healthcare and others over promotional claims involving infant and children’s products. It sought scientific support for claims about Nestle’s infant formulas and Zydus’s Complan drink; Abbott said it did not endorse or know about the social media content cited in its notice.
1. Regulator seeks evidence
India’s Food Safety and Standards Authority issued notices over products including Complan, Lactogen Pro 1 Powder, NAN Excella Pro Stage 1 and infant milk substitutes. It asked Nestle India for evidence supporting digestive and immune-system claims for its infant formulas and asked Zydus Wellness for scientific justification for Complan’s “grow taller, faster. clinically proven 2X growth” tagline.
2. Company responses
Nestle India said the regulator’s latest post reiterated issues raised on September 18 and that it had already submitted a detailed response. Abbott Healthcare said it was not involved in or aware of the Instagram content referenced in its notice until it received the notice, and did not endorse the content’s claims or representations.
